Drug evaluation: TA-2711E in the treatment of active distal ulcerative colitis.
Tanabe AAI LLC, a joint venture between Tanabe Seiyaku Co. Ltd. and aaiPharma Inc., is developing TA-2711E, an enema formulation of Tanabe's mucosal protectant ecabet, for the potential treatment of ulcerative colitis. By July 2004, phase III trials for ulcerative colitis had been initiated in Japan and phase II studies were ongoing in Europe and the U.S.; this remained the case in May 2006.
Monteleone
Giovanni
G
Università Tor Vergata, Dipartimento di Medicina Interna, Via Montpellier, 1, 00133 Rome, Italy. Gi.Monteleone@Med.uniroma2.it
Caprioli
Flavio
F
D045784:Abietanes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000285:Administration, Rectal; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004733:Enema; D006801:Humans; D016896:Treatment Outcome
D045784:Abietanes; D000893:Anti-Inflammatory Agents; D000897:Anti-Ulcer Agents; C061681:ecabet